IDH2 and neoplasm: The differential capacity of IDH mutations in D-2HG production is supported by observations from cell lines and clinical samples where tumours harbouring the IDH1R132H mutation generally have lower D-2HG levels compared to those with other IDH mutations [21, 24, 25, 29, 40] (but not in all [10]) though confounding factors such as tumour purity may influence these observations.